These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9546329)

  • 1. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome.
    Harper CM; Engel AG
    Ann Neurol; 1998 Apr; 43(4):480-4. PubMed ID: 9546329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital myasthenic syndromes: clinical and genetic analysis of 18 patients.
    Abicht A; Müller-Felber W; Fischer P; Jakob I; Kürz L; Rudel R; Mortier W; Pongratz D; Lochmüller H
    Eur J Med Res; 1997 Dec; 2(12):515-22. PubMed ID: 9498929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome.
    Fukudome T; Ohno K; Brengman JM; Engel AG
    Ann N Y Acad Sci; 1998 May; 841():199-202. PubMed ID: 9668240
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome.
    Harper CM; Engel AG
    Ann N Y Acad Sci; 1998 May; 841():203-6. PubMed ID: 9668241
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome.
    Croxen R; Newland C; Beeson D; Oosterhuis H; Chauplannaz G; Vincent A; Newsom-Davis J
    Hum Mol Genet; 1997 May; 6(5):767-74. PubMed ID: 9158151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome.
    Gomez CM; Maselli R; Gammack J; Lasalde J; Tamamizu S; Cornblath DR; Lehar M; McNamee M; Kuncl RW
    Ann Neurol; 1996 Jun; 39(6):712-23. PubMed ID: 8651643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome.
    Engel AG; Ohno K; Milone M; Wang HL; Nakano S; Bouzat C; Pruitt JN; Hutchinson DO; Brengman JM; Bren N; Sieb JP; Sine SM
    Hum Mol Genet; 1996 Sep; 5(9):1217-27. PubMed ID: 8872460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A congenital myasthenic syndrome refractory to acetylcholinesterase inhibitors.
    Triggs WJ; Beric A; Butler IJ; Roongta SM
    Muscle Nerve; 1992 Mar; 15(3):267-72. PubMed ID: 1313543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine.
    Harper CM; Fukodome T; Engel AG
    Neurology; 2003 May; 60(10):1710-3. PubMed ID: 12771277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine.
    Banwell BL; Ohno K; Sieb JP; Engel AG
    Neuromuscul Disord; 2004 Mar; 14(3):202-7. PubMed ID: 15036330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newly recognized congenital myasthenic syndrome associated with high conductance and fast closure of the acetylcholine receptor channel.
    Engel AG; Uchitel OD; Walls TJ; Nagel A; Harper CM; Bodensteiner J
    Ann Neurol; 1993 Jul; 34(1):38-47. PubMed ID: 7685992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis.
    Oh SJ; Hatanaka Y; Hemmi S; Young AM; Scheufele ML; Nations SP; Lu L; Claussen GC; Wolfe GI
    Muscle Nerve; 2006 Apr; 33(4):500-4. PubMed ID: 16392120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis.
    Imai T; Tsuda E; Hozuki T; Yamauchi R; Saitoh M; Hisahara S; Yoshikawa H; Motomura M; Kawamata J; Shimohama S
    Clin Neurophysiol; 2012 Sep; 123(9):1886-90. PubMed ID: 22386321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital myasthenia gravis in 13 smooth fox terriers.
    Miller LM; Lennon VA; Lambert EH; Reed SM; Hegreberg GA; Miller JB; Ott RL
    J Am Vet Med Assoc; 1983 Apr; 182(7):694-7. PubMed ID: 6841251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital myasthenic syndromes: experiments of nature.
    Engel AG; Ohno K; Sine SM
    J Physiol Paris; 1998 Apr; 92(2):113-7. PubMed ID: 9782453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis.
    Baslo MB; Deymeer F; Serdaroglu P; Parman Y; Ozdemir C; Cuttini M
    Neuromuscul Disord; 2006 Jul; 16(7):454-8. PubMed ID: 16806929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine prevents paraoxon-induced necrotizing myopathy in rats.
    De Bleecker JL; Meire VI; Pappens S
    Neurotoxicology; 1998 Dec; 19(6):833-8. PubMed ID: 9863772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine.
    Durmus H; Sticht H; Ceylaner S; Hashemolhosseini S; Deymeer F
    Acta Neurol Belg; 2021 Dec; 121(6):1755-1760. PubMed ID: 33030681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.
    Punga AR; Flink R; Askmark H; Stålberg EV
    Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes.
    Rostedt Punga A; Ahlqvist K; Bartoccioni E; Scuderi F; Marino M; Suomalainen A; Kalimo H; Stålberg EV
    Clin Neurophysiol; 2006 Jul; 117(7):1434-43. PubMed ID: 16737845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.